Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott F Huntington

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Therapeutic Advances in Hematology|February 14, 2022
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United StatesRory M Shallis, Rong Wang, Jan P Bewersdorf, et al.
Blood Advances|August 2, 2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyureaRong Wang, Rory M Shallis, Jessica M Stempel, et al.
Leukemia & Lymphoma|April 26, 2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United StatesXiaoyi Wang, Amer M Zeidan, Rong Wang, et al.
Plos One|May 12, 2021
Overall survival based on oncologist density in the United States: A retrospective cohort studySudeep K Siddappa Malleshappa, Smith Giri, Smit Patel, et al.
Leukemia & Lymphoma|October 23, 2023
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemiaScott F Huntington, Enrico de Nigris, Justin Puckett, et al.
Blood Advances|November 1, 2021
Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United StatesJan Philipp Bewersdorf, Stephanie Prozora, Nikolai A Podoltsev, et al.
Cancers|June 26, 2026
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline SettingScott F Huntington, Justin T Puckett, Beenish S Manzoor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's LymphomaScott F Huntington, Jessica R Hoag, Rong Wang, et al.
Leukemia & Lymphoma|December 28, 2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study<sup>†</sup>Amy J Davidoff, Xin Hu, Jan Philipp Bewersdorf, et al.
Cancer|June 17, 2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based studyAmer M Zeidan, Xin Hu, Jessica B Long, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Therapeutic Advances in Hematology|February 14, 2022
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United StatesRory M Shallis, Rong Wang, Jan P Bewersdorf, et al.
Blood Advances|August 2, 2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyureaRong Wang, Rory M Shallis, Jessica M Stempel, et al.
Leukemia & Lymphoma|April 26, 2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United StatesXiaoyi Wang, Amer M Zeidan, Rong Wang, et al.
Plos One|May 12, 2021
Overall survival based on oncologist density in the United States: A retrospective cohort studySudeep K Siddappa Malleshappa, Smith Giri, Smit Patel, et al.
Leukemia & Lymphoma|October 23, 2023
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemiaScott F Huntington, Enrico de Nigris, Justin Puckett, et al.
Blood Advances|November 1, 2021
Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United StatesJan Philipp Bewersdorf, Stephanie Prozora, Nikolai A Podoltsev, et al.
Cancers|June 26, 2026
Real-World Overall Survival and Time to Next Treatment Among Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Frontline SettingScott F Huntington, Justin T Puckett, Beenish S Manzoor, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 8, 2019
Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's LymphomaScott F Huntington, Jessica R Hoag, Rong Wang, et al.
Leukemia & Lymphoma|December 28, 2019
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study<sup>†</sup>Amy J Davidoff, Xin Hu, Jan Philipp Bewersdorf, et al.
Cancer|June 17, 2017
Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based studyAmer M Zeidan, Xin Hu, Jessica B Long, et al.
Pageof 9